Stock screener

TSHA

Conviction 47HealthcareScan · Thu, Sep 24, 2026

Taysha Gene Therapies, Inc. (TSHA) closed at $4.80 (-2.24%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 31, RS Rating 91, -31.2% from its 52-week high, -8.6% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

TSHA$4.80-2.24%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 4.33M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Taysha Gene Therapies, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.tayshagtx.com ↗
Price4.80
Change-2.24%
Gap-0.20%
Rel volume3.63×
Avg volume3.63M
Avg $ vol18.69M
SMA 205.31
SMA 505.73
SMA 2005.48
Price vs 50-16.27%
Price vs 200-12.40%
MA stackmixed
50/200 cross—
Supertrenddown · 5.56
RSI (14)31
MACD hist-0.02
MACD cross—
Stoch %K / %D15 / 15
ADX (14)18
+DI / −DI16 / 29
RSI divergence—
MACD divergence—
ATR %5.71%
ADR %4.44%
52w high6.98
52w low3.06
From 52w high-31.23%
Above 52w low+56.86%
New 52w highNo
SqueezeOff
Bollinger width24.76%
%B0.11
Donchian pos10.10%
Donchian high6.09
Donchian low4.66
AVWAP (52w high)5.90
vs AVWAP high-18.63%
AVWAP (52w low)5.13
vs AVWAP low-6.41%
OBV trendDown
Chaikin MF (20)-0.18
Today vs 20d3.63×
Avg vol (14d)4.33M
Avg vol (20d)3.63M
Avg $ vol (20d)18.69M
Market cap1.56B
RS Rating91 / 99
RS 3m (vs SPY)-27.20%
RS 6m (vs SPY)-12.01%
RS line new highNo
Trend template4/8
Technical rank30.9
1 week-6.98%
1 month-22.58%
3 months-22.71%
6 months+4.80%
1 year+64.38%
YTD-8.57%
P/E-14.35
P/B4.04
P/S160.03
P/FCF-16.67
EPS-0.3400
Div yield—
ROE-28.14%
ROA-23.17%
Debt/Eq0.13
Current17.76
EV/EBITDA—
Gross margin—
Net margin—
Rev growth17.28%
EPS growth-22.06%
Price target14.13
Target upside194.38%
Analyst ratingBuy
Institutional97.29%
Ent. value1.16B
Revenue0
Net income-46.64M
Gross profit—
Free cash flow-93.83M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out287.36M
Employees99
ListedThu, Sep 24, 2020
Free float228.89M
Float %83.6%
Short interest46.8M
Days to cover19.4d
Short volume53.3%
Squeeze score89 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.13 vs −$0.11
Last surprise-18.2% miss
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank30.9 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance6.64
Support4.93
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in TSHA

All disclosures →
No recent disclosed trades by Congress in TSHA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TSHA · open-market 1 sell

InsiderSideShares
Nagendran Sukumar
President and Head of R&D · Common Stock · 2026-07-10
Sell200K
Stalfort John A III
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Stalfort John A III
Director · Common Stock · 2026-06-01
Other—
Long Alison S
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Long Alison S
Director · Common Stock · 2026-06-01
Grant21.34K
Stalfort John A III
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K
Sepp-Lorenzino Laura
Director · Common Stock · 2026-06-01
Grant21.34K
Donenberg Phillip B.
Director · Common Stock · 2026-06-01
Grant21.34K
Sepp-Lorenzino Laura
Director · Stock Option (right to buy) · 2026-06-01
Grant42.67K

SEC filings

EDGAR filings in TSHA · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.